Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2

  title={Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2},
  author={Cameron S. Metcalf and Misty D. Smith and Brian D. Klein and Daniel R. McDougle and Liuyin Zhang and Grzegorz Bulaj},
  journal={Neurochemical Research},
The potential clinical utility of galanin peptidic analogs has been hindered by poor metabolic stability, lack of brain penetration, and hyperglycemia. In addition to possessing potent anticonvulsant efficacy, galanin analogs are analgesic in various assays. The purpose of these studies was to evaluate the lead galanin receptor type 2 (GalR2)-preferring analog, NAX 810-2, in various pain assays, as well as determine any potential for insulin inhibition, growth hormone stimulation, and cognitive… 

Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake

It is shown that the effect of M89b on food intake is indeed mediated by GAL2R, indicating that the first demonstration of in vivo activity of an intranasally administered lanthipeptide is a promising candidate for clinical application as a galanin-related peptide-based therapeutic.

Galanin Analogs Prevent Seizure-Induced Respiratory Arrest

These data demonstrate that galanin agonists may be protective against post-ictal respiratory collapse and may represent a novel potential therapy in SUDEP-susceptible individuals.

Galanin analogs prevent mortality from seizure-induced respiratory arrest in mice

Data demonstrate that galanin analogs may be protective against post-ictal respiratory collapse, and may represent a critical change that predisposes individuals to SUDEP.

Music-Enhanced Analgesia and Antiseizure Activities in Animal Models of Pain and Epilepsy: Toward Preclinical Studies Supporting Development of Digital Therapeutics and Their Combinations With Pharmaceutical Drugs

How enriched environment (EE) can serve as a preclinical surrogate for testing combinations of non-pharmacological modalities and drugs for the treatment of pain and other chronic diseases is discussed, and a new paradigm for preclinical and clinical development of therapies leading to drug-device combination products for neurological disorders, depression and cancer is proposed.

Evaluation of antiseizure drug efficacy and tolerability in the rat lamotrigine‐resistant amygdala kindling model

This model of pharmacoresistant epilepsy has been incorporated into the testing scheme utilized by the Epilepsy Therapy Screening Program (ETSP).

Co‐expression gene modules involved in cisplatin‐induced peripheral neuropathy according to sensitivity, status, and severity

The results provide possible targets and mechanism insights into the development and progress of CIPN, which can guide further transformation and pre‐clinical research.

Synergistic effects of the galanin analog 810–2 with the antiseizure medication levetiracetam in rodent seizure models

The lead galanin analog 810–2 is systemically bioavailable and reduces seizures when administered alone and requires a better understanding of the use of this analog in combination with approved ASMs to be considered for add‐on therapy in patients with epilepsy.



Analgesic Properties of a Peripherally Acting and GalR2 Receptor–Preferring Galanin Analog in Inflammatory, Neuropathic, and Acute Pain Models

Preclinical studies of a monodisperse oligoethylene glycol–containing galanin analog, NAX 409-9, in rodent analgesic and safety models illustrate that this nonbrain-penetrating galan in analog reduces pain behaviors in several models and does not produce some of the dose-limiting toxicities associated with other analgesics.

Preclinical evaluation of intravenous NAX 810‐2, a novel GalR2‐preferring analog, for anticonvulsant efficacy and pharmacokinetics

NAX 810‐2, a galanin receptor subtype 2 (GalR2)‐preferring galan in analog, possesses 15‐fold greater affinity for GalR2 over GalR1 and protects against seizures in the mouse 6 Hz, corneal kindling, and Frings audiogenic seizure models.

Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities.

T truncated galanin analogues in which nonessential amino acid residues were replaced by cationic and/or lipoamino acid residues prevented seizures in the 6 Hz mouse model of epilepsy following intraperitoneal administration and may lead to development of first-in-class antiepileptic drugs.

Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests.

The present work uses the tripeptidomimetic galnon and displays its presumed pharmacophores on a rigid molecular scaffold and provides an example of a systemically active compound based on a scaffold that mimics protein surfaces.

Anticonvulsant activity of a nonpeptide galanin receptor agonist

  • K. SaarA. Mazarati Ü. Langel
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 2002
Findings introduce a systemically active nonpeptide galanin agonist anticonvulsant through this receptor subtype.

Analgesic neuropeptide W suppresses seizures in the brain revealed by rational repositioning and peptide engineering.

The results suggest that the combination of neuropeptide repositioning and engineering NPW analogues that penetrate the blood-brain barrier could provide new drug leads, not only for the treatment of epilepsy and pain but also for studying effects of this peptide on regulating feeding and energy metabolism coupled to leptin levels in the brain.

Introduction of lipidization–cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities

  • B. R. GreenK. White G. Bulaj
  • Biology, Chemistry
    Journal of peptide science : an official publication of the European Peptide Society
  • 2010
The results suggest that the combination of lipidization and cationization may be an effective strategy for improving systemic bioavailability and metabolic stability of various neuroactive peptides.